MENLO PARK, Calif., Nov. 11, 2010 /PRNewswire/ -- SRI International, an independent nonprofit research and development organization, announced today that Joseph Perrone, Sc.D., has joined SRI International’s Center for Advanced Drug Research (CADRE) in Shenandoah Valley, Virginia. In his new role, Dr. Perrone will head CADRE’s molecular diagnostic efforts, including its rare and neglected diseases program.
Dr. Perrone is an experienced marketing and business development executive who has led global teams and developed successful strategic alliances. His leadership guided a team to develop pioneering instrumentation and rapid diagnostic tests for infectious and tropical diseases. Additionally, Dr. Perrone opened new markets and developed a profitable international business throughout Africa, Asia, Latin America and Europe.
“Joe Perrone is an accomplished manager, with exceptional ability to work closely with public health programs and bridge the gap between marketing and scientific challenges,” said Krishna Kodukula, Ph.D., CADRE executive director. “His results-oriented approach and significant experience building creative and innovative teams will be an asset to SRI.”
Prior to joining SRI, Dr. Perrone served as president of JBP Consulting. His past experience includes serving as Vice President of Strategic Initiatives and Business Development at the American Association for Clinical Chemistry and Vice President of Standards, Certification, and Product Development at American Type Culture Collection.
Earlier, he was Vice President of the Technology Transfer Office at the University of Maryland Biotechnology Institute. Dr. Perrone previously served as the Director of Business Development and R&D Team Manager at Becton Dickinson, where he was responsible for the rapid manual test business, technology assessment, and clinical trials in international markets.
Dr. Perrone received his Sc.D. from Johns Hopkins University and completed a postdoctoral fellowship at Harvard University. He has served as an advisor to the World Health Organization (WHO) and on the WHO diagnostic steering committee. He has received numerous marketing awards, including the R&D 100 award. Dr. Perrone has also served on the boards of FASGen and Legacy Direct, and is an advisor to Instantlabs.
About SRI’s Center for Advanced Drug Research (CADRE)
SRI established the Center for Advanced Drug Research (CADRE) to improve the productivity of the pharmaceutical industry, help our nation respond to biothreats, and develop life-saving treatments for rare and neglected diseases. CADRE’s mission is to create new therapeutics, diagnostics, and vaccines for infectious and other diseases and for biodefense. CADRE combines and partners with SRI’s well-established expertise in drug discovery, computational biology, and preclinical development with a new proteomics laboratory to develop these solutions.
About SRI’s Biosciences Division
SRI’s Biosciences division carries out basic research, drug discovery, and drug development, and provides contract (CRO) services. SRI has all of the resources necessary to take R&D from “Idea to IND"®from initial discovery to the start of human clinical trialsand specializes in cancer, immunology and inflammation, infectious disease, and neuroscience. SRI’s product pipeline has yielded marketed drugs, therapeutics currently in clinical trials, and additional programs in earlier stages. In its CRO business, SRI has helped government and commercial clients and partners advance many drugs into patient testing. SRI is also working to create the next generation of technologies in areas such as diagnostics, drug delivery, medical devices, and systems biology.
About SRI International
Silicon Valley-based SRI International is one of the world’s leading independent research and technology development organizations. SRI, which was founded by Stanford University as Stanford Research Institute in 1946 and became independent in 1970, has been meeting the strategic needs of clients and partners for more than 60 years. Perhaps best known for its invention of the computer mouse and interactive computing, SRI has also been responsible for major advances in networking and communications, robotics, drug discovery and development, advanced materials, atmospheric research, education research, economic development, national security, and more. The nonprofit institute performs sponsored research and development for government agencies, businesses, and foundations. SRI also licenses its technologies, forms strategic alliances, and creates spin-off companies. In 2009, SRI’s consolidated revenues, including its wholly owned for-profit subsidiary, Sarnoff Corporation, were approximately $470 million. Sarnoff Corporation, a leader in vision, video, and semiconductor innovations, will be fully integrated into SRI effective January 1, 2011.
SOURCE SRI International
